Central nervous system (CNS) injuries affect all levels of society indiscriminately, resulting in functional and behavioral deficits with devastating impacts on life expectancies, physical and emotional wellbeing. Considerable literature exists describing the pathophysiology of CNS injuries as well as the cellular and molecular factors that inhibit regrowth and regeneration of damaged connections. Based on these data, numerous therapeutic strategies targeting the various factors of repair inhibition have been proposed and on-going assessment has demonstrated some promising results in the laboratory environ. However, several of these treatment strategies have subsequently been taken into clinical trials but demonstrated little to no improvement in patient outcomes. As a result, options for clinical interventions following CNS injuries remain limited and effective restorative treatment strategies do not as yet exist. This review discusses some of the current animal models, with focus on nonhuman primates, which are currently being modeled in the laboratory for the study of CNS injuries. Last, we review the current understanding of the mechanisms underlying repair/regrowth inhibition and the current trends in experimental treatment strategies that are being assessed for potential translation to clinical applications.
In the United States, the incidence of CNS injuries per year are estimated to be (average numbers; Figure 1 ): TBI, 1.7million [5] ; SCI, 12,000 [6] ; pHI, 4,800 [7] and strokes, 750,000 [8] . Even so, there are no effective restorative or pharmacological strategies developed for the treatment of CNS injuries in humans as yet and current options for clinical interventions remain limited.
Although several treatment strategies have been previously brought to clinical trials based on optimistic experimental results, these trials fail to demonstrate improvements in functional outcomes [9] . Failure of these trials may be due in part to lack of understanding of the numerous sources of inhibition of repair present in the injured CNS. Though recent studies have made great strides to better understand the complex cellular and molecular mechanisms underlying the pathophysiology of injury, many questions still remain unanswered. Furthermore, comprehensive pre-clinical testing of any novel therapeutic strategies for the treatment of CNS injuries is necessary using appropriate animal models before they can be brought to human clinical trials.
In this review, we discuss current animal models, with focus on the nonhuman primate (NHP), being employed in the study of CNS injuries. We also evaluate current understanding of the cellular and molecular factors that impede axonal regrowth and regeneration, inhibiting functional recovery following CNS injuries. Finally, we discuss the recent trends in therapeutic strategies being developed and assessed in the laboratory, which may translate into a suitable intervention for the treatment of CNS injury in the human.
Current models of CNS injury research: The importance of the nonhuman primate
To investigate the cellular and molecular events surrounding regeneration, various animal models have been developed to mimic the different types of CNS injuries. These models are important to examine the pathophysiology of injurious conditions affecting the CNS. Furthermore, they are essential for testing novel therapeutic strategies aimed at counteracting the various aspects of CNS injury in a reliable and reproducible manner.
Since the 1990s, rodent models of CNS injuries have dominated the field (reviewed by [1] ), being the most widely used species in TBI and SCI research. However, other species such as dogs [10] , pigs [11] , sheep [12] , cats [13, 14] , zebrafish [15] and nonhuman primates (NHP) have been used to develop animal models of CNS injuries [16, 17] . assess sensory acuity with greater parallels to functional deficits observed in human patients. temporary application of surgical clips [25] ; 2.
ligatures [26] ; 3. endovascular techniques using inflatable cuff-type catheters [27] or detachable coils [24] ; 4. autologous clot embolism [28] ; and, 5. vasoconstrictor administration [23] . In most MCAO studies, a reproducibly large zone of infarct is usually observed in the cortical and subcortical MCA perfusion territories.
More focal models of ischemic stroke have also been developed through occlusion of smaller arteries (usually the distal M1 portion of the MCA), resulting in relatively smaller and more focal zone of infarcts affecting the M1 territory (for a review, see [18] ). The consequence of MCAO on functional outcomes depends greatly on the type (reversible vs. permanent occlusion) severity and extent (proximal vs. distal branch occlusion) of infarct and may range from loss of sensorimotor capacity to death. Some progress has also been made in developing a NHP stroke model in the anterior cerebral artery territory [24] . However to the best of our knowledge, no previous attempts have been made to develop a model for focal 
Traumatic Brain injury (TBI)
TBI can be broadly categorized into focal or diffuse injuries. Focal TBI (fTBI) is a result of external force vectors that are focused on a narrow and limited region of the brain, such as contusions and penetrating brain injuries [29] . Diffuse-type TBI (dTBI) usually presents as concussion or diffuse axonal injuries, where linear and angular acceleration / deceleration forces causes stretching and twisting of axons, predominantly in the cortical white matter and corpus callosum [30] . dTBI is commonly seen in [33] ). Although ablative injury is primarily observed following penetrating, ballistic or battlefield neurotrauma [34] , this model bears more relevance to neurological deficits resulting as from the surgical resection of damaged cortical tissue, due to traumatic injury, tumours or masses [35] and surgical interventions for the treatment of epilepsy [36] . Surgically induced lesions of the orbital frontal cortex (OFC; Walker's area 11 and 13) and amygdala have also been preformed on the rhesus monkey (Macaca mulatta) using either aspiration or intracortical injections of neurotoxic compounds (ibotenic acid [37] [38] [39] [4] . A common sequelae of pHI is periventricular leukomalacia (PVL) which results in white matter lesions surrounding the periventricular region [45] . In some cases, intracerebral and intraventricular hemorrhages can occur as a result of by pHI [46] . The neurogenic zones (subventricular zone; SVZ and dentate gyrus; DG in the hippocampus) are particularly susceptible to HI insults. Studies have demonstrated significant declines in SVZ cell survival [47] and increased apoptotic response in the DG [48] following HI injury compared to agematched controls. The pathological impacts on the neurogenic zones may account for the developmental deficits that result from HI insults during early life. It is well established that the major pathological processes underlying HI injury is the deprivation of glucose and oxygen supplies, ultimately leading to necrotic cell death [49] . The subsequent reperfusion injury also exacerbates neurological damage by increasing oxidative stress and excitotoxicity [4] . Selective degeneration of interneurons in the NHP motor cortex has been demonstrated following perinatal HI insults [50] . NHP models And while studies in small-animal models (rabbit, rodents) have been instrumental in addressing the genetic and biochemical events associated with pHI [57, 58] , the temporal and pathophysiological sequelae of the injury does not detail the same mechanisms that might be occurring in the primate brain. To that end, the further development of NHP models of pHI is important for the purpose of investigating the consequences of pHI in a system that is more reflective of the human condition and allow better corollary for future therapeutic developments.
Spinal Cord injuries (SCI)
The consequence of SCI commonly leads to paraplegia or quadriplegia, severely impeding locomotor and skilled limb functions as well as manual dexterity. Animal models of SCI, especially in rodents [59] [60] [61] [62] 
Molecular and cellular consequences of CNs injury: implications for regeneration
In the acute stage (within minutes) following a CNS injury (Figure 2A ), the first wave of cell death (necrosis) affecting both neuronal and glial cell types usually occurs as a direct consequence of the injury, this zone is known as the lesion / necrotic core [80] . The lesion penumbra ( Figure 2B ), an area of tissue surrounding the lesion core, that is less severely affected by the lesion, remains metabolically active [81] depending on the severity and type of lesion. The first wave of necrosis, occurring in the lesion core, is characterized by cell swelling and mitochondria / endoplasmic reticulum breakdown followed by rupturing of the plasma, organelle and nuclear membranes [82] . Disruption of the blood brain barrier (BBB) may be caused by the injury or the resulting intracerebral hemorrhage [29, 83] , which may also initiate a localized neuroinflammatory response from chemotactic recruitment of immune cells [84] . Subsequently, rapid recruitment of microglia (resident macrophages) and astrocytes to the affected area occurs to limit the extent of damage and remove debris from necrotic cells.
In the subacute period after injury (hoursdays; Figure 2B ), a second wave for cell death (necrosis and apoptosis), known as the secondary injury can occur in the lesion penumbra. This can be caused by a variety of factors. For example, prolonged hypoxia or ischemia, excitotoxic and oxidative stress caused by reperfusion (after transient cerebral ischemia [85] ) injuries and free radicals [86] or debris from necrotic cells, homeostatic and osmotic stress from cerebral edema [83] and anterograde degeneration of neuronal processes [87] from axonal shearing or loss of terminal fields. Anterograde degeneration of long projecting axons from areas distal to the lesion site (such as thalamocortical projecting axons) may also result in distal neuronal cell death that is secondary to the injury. The result of the secondary wave of cell death leads to a compounded effect on astrocyte and microglial recruitment to the lesion core and penumbra. Furthermore, oxidative stress [88] and axonal degeneration can result in death of oligodendrocyte populations that myelinate the affected axons [89] . The myelin debris left behind by apoptotic oligodendrocytes in addition to that resulting from the initial trauma further exaggerates the unfavorable environment at the lesion site and penumbra. 
Inhibition of CNS regeneration after injury
The swollen dystrophic ends of damaged axons first described by Cajal [91] were originally thought to be incapable of regeneration, eventually succumbing to anterograde degeneration (Wallerian degeneration [92] ) resulting in neuronal death [87, 93] . However, more recent investigations of spinal cord [94, 95] and cortical neurons [96] have demonstrated the development of regenerative growth cones after axonal damage but which are inhibited in the non-permissive environment at the lesion site. In vitro studies using neocortical neurons have established that these regenerative growth cones retain some intrinsic capacity for pathfinding [97] in permissive environments. In the acute stages after injury (A), the first wave of necrotic cell death occurs as a direct consequence of the trauma. Disruption of the blood brain barrier (BBB) from intracerebral hemorrhages may also result in ischemia, hemodynamic stress and localized inflammatory response from chemotactic recruitment of immune cells. Local cellular responses include recruitment of astrocytes and microglia to the lesion core occures to limit the extent of damage and to remove debris from necrosed cells. In the subacute stages of the injury (B), a second wave of cell death can occur in the metabolically active region surrounding the lesion core (penumbra). This secondary injury is usually a result of excitotoxic, oxidative and osmotic stress caused by repurfusion injuries and/or chemical, molecular and cellular debris from the lesion core. Anterograde degeneration of axons from the lesion core also results in distal cell death in upstream areas and increased presence of oligodendrocyte/myelin debris. The result of primary and secondary injuries is a CNS environment that is severely inhibitory to regrowth, rerouting and reconnection of damaged axons. To this end, novel therapeutic strategies (C) aims to promote regeneration of damage connections following adult CNS injuries by: 1. Counteracting the inhibitory environment at the injury site through targeted molecular strategies and introducing localized plasticity using chondroitinase ABC (chABC), 2. Promoting survival of injured neurons and axons through delivery of growth and neuroprotective factors and 3. Through integration of endogenous and exogenous stem/progenitor cell therapies. The administration of individual or combinatorial therapeutic strategies would potentially counteract the growth-inhibitory environment in the damaged CNS to promote survivability as well as the rerouting and regeneration of damaged axons to repair damaged neural circuitry.
cascade of inhibitory molecules present at the lesion site contributes significantly to the inhibition of neurite and axonal outgrowth after injury [98, [105] [106] [107] .
Chondroitin sulfate proteoglycans The high affinity interactions of PirB [130] [131] [132] [133] [134] and of the GPI-linked NgR with Nogo66 [130, 135] , MAG [136] [137] [138] and OMgp [138, 139] are the major source of MAI-associated neurite review, see [116] ). Early in vitro studies [106] and subsequent examination of postfixed [148] and live rat cerebral tissues (in vivo [149] ) demonstrated the capacity of chABC to 
Suppression of EphA4 activation
The strategy of blocking EphA4 activation that is significantly upregulated on astrocytes at the site of injury (in rodents [102] , and primates [33] ), has been proposed to attenuate Grafting of BDNF expressing fibroblasts following an axotomy has been reported to promote axonal survival and regeneration [171] [172] [173] , as well as rescue limb function after rat SCI [13, 174] . Administration of TGFα, a mitogenic growth factor, either via intracatheter infusion [175] or via overexpression through adeno-associated virus injection [176] following TBI in rats [177, 178] . FGF-2 treatment improved functional recovery following earlyadolescent and neonatal injury to the rat motor cortex [179, 180] as well as conferring neuroprotective roles against hypoxic-ischemic insult to the perinatal rat brain [181] . Although these studies demonstrate promising results for growth factor therapy following brain injury, further work will be required to determine if this strategy will indeed promote neuroprotection and axonal regeneration in the NHP models of injury before moving on to human clinical trials.
Stem/progenitor cells therapy: endogenous vs exogenous
Research over the last 15-20 years has overturned the dogma that the generation of neurons in the mammalian CNS is restricted to development. It is now firmly established that new neurons are generated in the subventricular zone (SVZ), and hippocampus throughout adult life [182, 183] . Just as significant, is the recent finding that nonneurogenic compartments of the uninjured adult rodent [184] , marmoset [185] and human [186] neocortex contain multipotent neural precursor cells (NPCs) that exhibit latent neurogenic potential in vitro.
However, the presence of neurogenesis in the adult human CNS remains strongly disputed, citing evolutionary and interspecies differences in cellular mechanisms [187] . One study in particular, demonstrated an 18-month [188, 189] types of cortical injury [190, 191] . Moreover, significant synaptic plasticity and neurogenesis occurs following CNS injury in higher order mammals, including NHP [192] [193] [194] and differentiate into cells with neuronal and oligodendroglial characteristics [196] . Grafting of engineered human neural stem cells onto the rat forebrain following hypoxic-ischemic injury promoted axonal sprouting and improved recovery [197, 198] . Stem cell transplantation therapies have also been proposed for the treatment of retinal diseases [199] , ischemic injuries [200] and TBI [201, 202] . announced by Geron [205, 206] , but has since been discontinued, citing funding and financial reasons [207] . Implantation of the NT2/D1 precursor cell line (human embryonic carcinoma-derived) has also been previously trialed in human stroke patients. Cells were implanted via stereotaxic-guided injection into the basal ganglia of stroke patients. Postrecovery functional/neurological assessments demonstrated trending improvements but were statistical insignificant [208] .
Although the conceptual applications of stem/progenitor cell therapy seems promising, it is our opinion that further animal trials are 
